- 1.
Mijnendonckx, K., Leys, N., Mahillon, J., Silver, S. & Van Houdt, R. Antimicrobial silver: uses, toxicity and potential for resistance. BioMetals 26, 609–621 (2013).
- 2.
Molling, J. W., Seezink, J. W., Teunissen, B. E., Muijrers-Chen, I. & Borm, P. J. Comparative performance of a panel of commercially available antimicrobial nanocoatings in Europe. Nanotechnol. Sci. Appl. 7, 97–104 (2014).
- 3.
Silver nanoparticles market by application (electronics & electrical, healthcare, food & beverages, textiles) and segment forecasts to 2022. GrandView Research (2015); https://www.grandviewresearch.com/industry-analysis/silver-nanoparticles-market
- 4.
Panacek, A. et al. Silver colloid nanoparticles: synthesis, characterization, and their antibacterial activity. J. Phys. Chem. B 110, 16248–16253 (2006).
- 5.
Franci, G. et al. Silver nanoparticles as potential antibacterial agents. Molecules 20, 8856–8874 (2015).
- 6.
Duran, N. et al. Silver nanoparticles: a new view on mechanistic aspects on antimicrobial activity. Nanomedicine 12, 789–799 (2016).
- 7.
Lara, H. H., Ayala-Nunez, N. V., Turrent, L. & Padilla, C. R. Bactericidal effect of silver nanoparticles against multidrug-resistant bacteria. World J. Microbiol. Biotechnol. 26, 615–621 (2010).
- 8.
Graves, J. L. et al. Rapid evolution of silver nanoparticle resistance in Escherichia coli. Front. Genet. 6, 42 (2015).
- 9.
Gunawan, C., Teoh, W. Y., Marquis, C. P. & Amal, R. Induced adaptation of Bacillus sp. to antimicrobial nanosilver. Small 9, 3554–3560 (2013).
- 10.
Panacek, A. et al. Bacterial resistance to silver nanoparticles and how to overcome it. Nat. Nano. 13, 65–71 (2018).
- 11.
Losasso, C. et al. Antibacterial activity of silver nanoparticles: sensitivity of different Salmonella serovars. Front. Microbiol. 5, 227 (2014).
- 12.
Valentin, E. et al. Heritable nanosilver resistance in priority pathogen: a unique genetic adaptation and comparison with ionic silver and antibiotics. Nanoscale 12, 2384–2392 (2020).
- 13.
Gunawan, C. et al. Widespread and indiscriminate nanosilver use: genuine potential for microbial resistance. ACS Nano 11, 3438–3445 (2017).
- 14.
Haefeli, C., Franklin, C. & Hardy, K. Plasmid-determined silver resistance in Pseudomonas stutzeri isolated from a silver mine. J. Bacteriol. 158, 389–392 (1984).
- 15.
Li, X. Z., Nikaido, H. & Williams, K. E. Silver-resistant mutants of Escherichia coli display active efflux of Ag+ and are deficient in porins. J. Bacteriol. 179, 6127–6132 (1997).
- 16.
Gupta, A., Matsui, K., Lo, J. F. & Silver, S. Molecular basis for resistance to silver cations in Salmonella. Nat. Med. 5, 183–188 (1999).
- 17.
Silver, S. Bacterial silver resistance: molecular biology and uses and misuses of silver compounds. FEMS Microbiol. Rev. 27, 341–353 (2003).
- 18.
Pelgrift, R. Y. & Friedman, A. J. Nanotechnology as a therapeutic tool to combat microbial resistance. Adv. Drug Deliv. Rev. 65, 1803–1815 (2013).
- 19.
Wang, L., Hu, C. & Shao, L. The antimicrobial activity of nanoparticles: present situation and prospects for the future. Int J. Nanomed. 12, 1227–1249 (2017).
- 20.
Johnston, K. A. et al. Impacts of broth chemistry on silver ion release, surface chemistry composition, and bacterial cytotoxicity of silver nanoparticles. ES: Nano 5, 304–312 (2018).
- 21.
Johnston, K. A., Smith, A. M., Marbella, L. E. & Millstone, J. E. Impact of as-synthesized ligands and low-oxygen conditions on silver nanoparticle surface functionalized. Langmuir 32, 3820–3826 (2016).
- 22.
Bastus, N. G., Merkoci, F., Piella, J. & Puntes, V. Synthesis of highly monodisperse citrate-stabilized silver nanoparticles of up to 200 nm: kinetic control and catalytic properties. Chem. Mater. 26, 2836–2846 (2014).
- 23.
Ivanova, E. P., Bazaka, K. & Crawford, R. J. in New Functional Biomaterials for Medicine and Healthcare Ch. 3, 71–99 (Woodhead, 2014).
- 24.
Olofsson, S. K. & Cars, O. Optimizing drug exposure to minimize selection of antibiotic resistance. Clin. Infect. Dis. 45, S129–S136 (2007).
- 25.
Gullberg, E. et al. Selection of resistant bacteria at very low antibiotic concentrations. PLoS Pathog. 7, e1002158 (2011).
- 26.
Adam, M., Murali, B., Glenn, N. O. & Potter, S. S. Epigenetic inheritance based evolution of antibiotic resistance in bacteria. BMC Evol. Biol. 8, 52 (2008).
- 27.
George, A. M. & Levy, S. B. Amplifiable resistance to tetracycline, chloramphenicol, and other antibiotics in Escherichia coli: involvement of a non-plasmid-determined efflux of tetracycline. J. Bacteriol. 155, 531–540 (1983).
- 28.
Zhao, Y. et al. Small molecule-capped gold nanoparticles as potent antibacterial agents that target Gram-negative bacteria. J. Am. Chem. Soc. 132, 12349–12356 (2010).
- 29.
Ji, F. et al. Tetrabromobisphenol A (TBBPA) exhibits specific antimicrobial activity against Gram-positive bacteria without detectable resistance. Chem. Commun. 53, 3512–3515 (2017).
- 30.
Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement Vol. 30(1) (Approved Standard M100-S20, Clinical and Laboratory Standards Institute, 2010).
- 31.
Silver, S. in Molecular Biology, Pathogenicity, and Ecology of Bacterial Plasmids (eds Levy, S. B. et al.) 179–189 (Plenum, 1981).
- 32.
Flynn, K. M., Cooper, T. F., Moore, F. B. G. & Cooper, V. S. The environment affects epistatic interactions to alter the topology of an empirical fitness landscape. PLoS Genet. 9, e1003426 (2013).
- 33.
Hall, A. E. et al. Environment changes epistasis to alter trade-offs along alternative evolutionary paths. Evolution 73, 2094–2105 (2019).
- 34.
Stabryla, L. M., Johnston, K. A., Millstone, J. E. & Gilbertson, L. M. Emerging investigator series: it’s not all about the ion: support for particle-specific contributions to silver nanoparticle antimicrobial activity. ES: Nano 5, 2047–2068 (2018).
- 35.
Sandoval-Motta, S. & Aldana, M. Adaptive resistance to antibiotics in bacteria: a systems biology perspective. WIREs Syst. Biol. Med 8, 253–267 (2016).
- 36.
Normark, B. H. & Normark, S. Evolution and spread of antibiotic resistance. J. Intern. Med. 252, 91–106 (2002).
- 37.
Lok, C.-N. et al. Proteomic identification of the cus system as a major determinant of constitutive Escherichia coli silver resistance of chromosomal origin. J. Proteome Res. 7, 2351–2356 (2008).
- 38.
Knetsch, M. L. & Koole, L. H. New strategies in the development of antimicrobial coatings: the example of increasing usage of silver and silver nanoparticles. Polymers 3, 340–366 (2011).
- 39.
Chopra, I. The increasing use of silver-based products as antimicrobial agents: a useful development or a cause for concern? J. Antimicrob. Chemother. 59, 587–590 (2007).
- 40.
Bridges, K., Kidson, A., Lowbury, E. J. L. & Wilkins, M. D. Gentamicin- and silver-resistant Pseudomonas in a burns unit. Brit. Med. J. 1, 446–449 (1979).
- 41.
Gudipaty, S. A. & McEvoy, M. M. The histidine kinase CusS senses silver ions through direct binding by its sensor domain. Chem. Biochem. 1844, 1656–1661 (2014).
- 42.
Affandi, T. & McEvoy, M. M. Mechanism of metal ion-induced activation of a two-component sensor kinase. Biochem. J. 476, 115–135 (2019).
- 43.
Cooper, V. S. Experimental evolution as a high-throughput screen for genetic adaptations. mSphere 3, e00121–18 (2018).
- 44.
Tajkarimi, M. et al. Selection for ionic- confers silver nanoparticle resistance in Escherichia coli. JSM Nanotechnol. Nanomed. 5, 1047 (2017).
- 45.
Randall, C. P., Gupta, A., Jackson, N., Busse, D. & O’Neill, A. J. Silver resistance in Gram-negative bacteria: a dissection of endogenous and exogenous mechanisms. J. Antimicrob. Chemother. 70, 1037–1046 (2015).
- 46.
Koskella, B., Taylor, T. B., Bates, J. & Buckling, A. Using experimental evolution to explore natural patterns between bacterial motility and resistance to bacteriophages. ISME J. 5, 1809–1817 (2011).
- 47.
Samad, T. et al. Swimming bacteria promote dispersal of non-motile Staphylococcal species. ISME J. 11, 1933–1937 (2017).
- 48.
Gauger, E. J. et al. Role of motility and the flhDC operon in Escherichia coli MG1655 colonization of the mouse intestine. Infect. Immun. 75, 3315–3324 (2007).
- 49.
Barker, C. S., Prub, B. M. & Matsumura, P. Increased motility of Escherichia coli by insertion sequence element integration into the regulatory region of the flhD operon. J. Bacteriol. 186, 7529–7537 (2004).
- 50.
Sanchez-Torres, V., Hu, H. & Wood, T. K. GGDEF proteins YeaI, YedQ, and YfiN reduce early biofilm formation and swimming motility in Escherichia coli. Appl. Microbiol. Biotechnol. 90, 651–658 (2011).
- 51.
Butler, M. T., Wang, Q. & Harshey, R. M. Cell density and mobility protect swarming bacteria against antibiotics. Proc. Natl Acad. Sci. USA 107, 3776–3781 (2010).
- 52.
Lai, S., Tremblay, J. & Deziel, E. Swarming motility: a multicellular behaviour conferring antimicrobial resistance. Environ. Microbiol. 11, 126–136 (2009).
- 53.
Sun, E. et al. Broad-spectrum adaptive antibiotic resistance associated with Pseudomonas aeruginosa mucin-dependent surfing motility. Antimicrob. Agents Chemother. 62, e00848–18 (2018).
- 54.
Zhang, H. et al. Stress resistance, motility and biofilm formation mediated by a 25kb plasmid pLMSZ08 in Listeria monocytogenes. Food Control 94, 345–352 (2018).
- 55.
Asadishad, B., Hidalgo, G. & Tufenkji, N. Pomegranate materials inhibit flagellin gene expression and flagellar-propelled motility of uropathogenic Escherichia coli strain CFT073. FEMS Microbiol. Lett. 334, 87–94 (2012).
- 56.
Paramelle, D. et al. A rapid method to estimate the concentration of citrate capped silver nanoparticles from UV-visible light spectra. Analyst 139, 4855–4861 (2014).
- 57.
Zhang, W., Crittenden, J., Li, K. & Chen, Y. Attachment efficiency of nanoparticle aggregation in aqueous dispersions: modeling and experimental validation. Environ. Sci. Technol. 46, 7054–7062 (2012).
- 58.
Li, X., Lenhart, J. J. & Walker, H. W. Dissolution-accompanied aggregation kinetics of silver nanoparticles. Langmuir 26, 16690–16698 (2010).
- 59.
Ma, R. et al. Size-controlled dissolution of organic-coated silver nanoparticles. Environ. Sci. Technol. 46, 752–759 (2012).
- 60.
Biggest Threats and Data (Centers for Disease Control and Prevention, 2020); https://www.cdc.gov/drugresistance/biggest-threats.html
- 61.
Demirdjian, S. et al. Phosphatidylinositol-(3,4,5)-trisphosphate induces phagocytosis of nonmotile Pseudomonas aeruginosa. Infect. Immun. 86, 215–218 (2018).
- 62.
Deatherage, D. E. & Barrick, J. E. Identification of mutations in laboratory-evolved microbes from next-generation sequencing data using breseq. Methods Mol. Biol. 1151, 165–188 (2014).
- 63.
Narayanaswamy, V. P. et al. In vitro activity of novel glycopolymer against clinical isolates of multidrug-resistant Staphylococcus aureus. PLoS One 13, e0191522 (2018).
- 64.
Li, X. et al. Functional gold nanoparticles as potent antimicrobial agents against multi-drug-resistant bacteria. ACS Nano 8, 10682–10686 (2014).
- 65.
Landman, D., Salamera, J. & Quale, J. Irreproducible and uninterpretable polymyxin B MICs for Enterobacter cloacae and Enterobacter aerogenes. J. Clin. Microbiol. 51, 4106–4111 (2013).
- 66.
El-Halfawy, O. M. & Valvano, M. A. Antimicrobial heteroresistance: an emerging field in need of clarity. Clin. Microbiol. Rev. 28, 191–207 (2015).
- 67.
Baalousha, M. et al. The concentration-dependent behavior of nanoparticles. Environ. Chem. 13, 1–3 (2015).
- 68.
Lecture 11: Antimicrobial Susceptibility Testing—Broth Dilution. Online video clip. Technical Univ. Denmark (n.d); https://www.coursera.org/lecture/antimicrobial-resistance/lecture-11-antimicrobial-susceptibility-testing-broth-dilution-VeNw0
- 69.
Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically 9th edn, Vol. 32(2) (Approved Standard M7-A9, Clinical and Laboratory Standards Institute, 2012).
- 70.
Riley, M. et al. Escherichia coli K-12: a cooperatively developed annotation snapshot—2005. Nucleic Acids Res. 34, 1–9 (2006).
Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.nature.com/articles/s41565-021-00929-w